Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 5/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | PRKCI | P41743 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30820060 | 1.00 | GPR3 (0.47) | GPR3KDM4ECYP2A6CYP1A2POLB | |
| SCHEMBL16552260 | 0.78 | KDM4E (0.50) | GPR3KDM4ECYP2A6CYP1A2POLB | |
| SCHEMBL12258315 | 0.78 | GPR3 (0.50) | GPR3KDM4ECYP2A6CYP1A2ALDH1A1 | |
| SCHEMBL30901311 | 0.78 | KDM4E (0.50) | GPR3KDM4ECYP2A6CYP1A2POLB | |
| SCHEMBL17942817 | 0.77 | KDM4E (0.48) | GPR3KDM4ECYP2A6CYP1A2POLB | |
| SCHEMBL25170252 | 0.75 | KDM4E (0.47) | GPR3KDM4ECYP2A6CYP1A2POLB | |
| SCHEMBL15401178 | 0.75 | KDM4E (0.47) | GPR3KDM4ECYP1A2POLBALDH1A1 | |
| SCHEMBL7315366 | 0.75 | POLB (0.50) | GPR3KDM4ECYP2A6CYP1A2POLB | |
| SCHEMBL28483779 | 0.75 | KDM4E (0.47) | GPR3KDM4ECYP2A6CYP1A2POLB | |
| SCHEMBL16144709 | 0.75 | GPR3 (0.47) | GPR3KDM4ECYP2A6CYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441727-B2 | Tricyclic compounds as inhibitors of KRAS | INCYTE CORPORATION (US) | 2025-10-14 | — | — | US | disclosed |
| US-20240182444-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-06-06 | — | — | US | disclosed |
| EP-4367117-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | Incyte Corporation (US) | 2024-05-15 | — | — | EP | disclosed |
| CN-111989321-B | KRAS G12C inhibitors | 米拉蒂治疗股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-117881680-A | Tricyclic compounds as KRAS inhibitors | 因赛特公司 | 2024-04-12 | — | — | CN | disclosed |
| US-20240101553-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230056631-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION | 2023-02-23 | — | — | US | disclosed |
| WO-2006029769-A1 | NOVEL 3-METHYL-7-BUTINYL-XANTHINES, PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-03-23 | — | — | WO | disclosed |
| EP-0975602-B1 | IMIDAZOLE AND IMIDAZOLINE DERIVATIVES AND USES THEREOF | GRUENENTHAL GMBH (DE) | 2005-06-15 | — | — | EP | disclosed |
| US-6777426-B2 | SELECTIVE AGONISTS FOR HUMAN ALPHA 2 ADRENERGIC RECEPTORS; TREATING PAIN, MIGRAINE, HEADACHES, GLAUCOMA; 2-(INDAN-5-YL)AMINO-2-IMIDAZOLINE FOR EXAMPLE | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-08-17 | — | — | US | disclosed |
| EP-0975602-A4 | IMIDAZOLE AND IMIDAZOLINE DERIVATIVES AND USES THEREOF | GRUENENTHAL GMBH (DE) | 2003-01-22 | — | — | EP | disclosed |
| US-20020019390-A1 | Imidazole and imidazoline derivatives and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-02-14 | — | — | US | disclosed |
| US-6294566-B1 | ENANTIOMORPHS REVERSE AND ADRENERGIC AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-09-25 | — | — | US | disclosed |
| US-6093727-A | A SELECTIVE AGONISTS FOR HUMAN ALPHA 2 RECEPTORS FOR TREATING DISORDERS AS HYPERTENSION, PAIN, GLAUCOMA, ALCOHOL AND DRUG WITHDRAWAL, ISCHEMIA, RHEUMATOID ARTHRITIS, MIGRAINE, COGNITIVE DEFICIENCY, SPASTICITY, DIARRHEA, NASAL CONGESTION | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-07-25 | — | — | US | disclosed |
| EP-0975602-A1 | IMIDAZOLE AND IMIDAZOLINE DERIVATIVES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-02-02 | — | — | EP | disclosed |
| US-5866579-A | SELECTIVE AGONISTS FOR CLONED HUMAN ALPHA-2 ADRENERGIC RECEPTORS. | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1999-02-02 | — | — | US | disclosed |
| WO-1998046572-A1 | IMIDAZOLE AND IMIDAZOLINE DERIVATIVES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1998-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12441727-B2 | Tricyclic compounds as inhibitors of KRAS | KRAS, NRAS, HRAS | GPR3 3927/4885KDM4E 4227/4885CYP2A6 3542/4885 |
| US-20230056631-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | GPR3 3769/4885KDM4E 4221/4885CYP2A6 3464/4885 |
| US-20020019390-A1 | Imidazole and imidazoline derivatives and uses thereof | ADRB2, ADRA2C, ADRB3 | GPR3 40/4885KDM4E 3834/4885CYP2A6 1239/4885 |
| US-20240182444-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | GPR3 4805/4885KDM4E 3205/4885CYP2A6 1619/4885 |
| US-20240101553-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | GPR3 1887/4885KDM4E 3689/4885CYP2A6 3834/4885 |
| US-20230373999-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | GPR3 1887/4885KDM4E 3689/4885CYP2A6 3834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.